For patients in which the driver oncogene is negative or unknown, immune checkpoint inhibitors (ICIs) alone or in combination with cytotoxic drugs, depending on the programmed cell death-ligand 1 (PD-L1) status in the tumor and the tissue type, have been introduced as first-line treatments. The gene discussed is CD274; the disease is neoplasm.